Alive & kicking..
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Saw this on Twitter
$metx pic.twitter.com/tM8uBlsc4g
— Dijontus (@soursaucey) October 29, 2021
METX 88% shorted. MOASS in progress
88% shorted. MOASS
METX . MOASS in progress. Load up
METX up 43%. Huge covering happening
METX.. BOOOM..
METX. Do yourself a favor and look. Crazy volume, .53 95mil float
METX 43 mil volume, 95mil.float @.49
METX take a look. Bitcoin news, huge volume already
L2, been many yrs , hope you have been well
METX 10mil volume already Bitcoin news
METX, bounce play, look at the volume
METX 1.3 billion traded last 2 days on Bitcoin news, 95 million float(supposedly)
Shorty tanked it yesterday. Looking for a bounce here
New to this board, old soul to IHUB.
METX 1.3 billion traded last 2 days on Bitcoin news, 95 million float(supposedly)
Shorty tanked it yesterday. Looking for a bounce here
Give him a week to increase shares and dilute the F out of this.
WTRH, Morgan Stanley just invested 10%
Volume is sick. See $2 +. Easily
FEDU, $15 mil reserved for share buy back
16 mil float. Check the accumulation chart. This is primed.
Good luck old friend
FEDU, 16mil float @.90, $15mil share buy back
Moving now
FEDU News-, Share Buy Back, 16mil Float
Four Seasons Education Announces Board Authorization to Repurchase up to US$15 Million
Source: PR Newswire (US)
SHANGHAI, Sept. 23, 2021 /PRNewswire/ -- Four Seasons Education (Cayman) Inc. ("Four Seasons Education" or the "Company") (NYSE: FEDU), a leading Shanghai-based educational company dedicated to providing comprehensive after-school education services with a focus on high-quality math education, today announced that effective on September 23, 2021, the board of directors of the Company (the "Board") approved a share repurchase program whereby Four Seasons Education is authorized to repurchase its own ordinary shares in the form of American depositary shares ("ADSs") with an aggregate value of up to US$15.0 million during the next twelve-month period. The Company plans to fund the repurchase program out of its available working capital, existing cash balance or future cash provided by operating activities.
The share repurchases under the 2021 program may be made from time to time through various means, including open market purchases and privately negotiated transactions. The per share price cap will be determined from time to time at the discretion of the Chief Executive Officer, as authorized by the Board. The proposed share repurchase may be effected on the open market at prevailing market prices, depending on a number of factors, including, but not limited to, share price, trading volume and general market conditions, along with the Company's working capital requirements, general business conditions and other factors, as well as subject to applicable rules of Rule 10b5-1 and/or Rule 10b-18 under the Securities Exchange Act of 1934, as amended.
Freaking Fridays.
Oh well.
For a 15m float, it's trading like a 100mil float.
Betting on an after hours run at this point.
It's being loaded
What's the share structure? Float?
EYPT NEWS EyePoint Pharmaceuticals Receives $9.5 Million in Upfront Cash from Ocumension Therapeutics Under Expanded License Agreements...
Source: GlobeNewswire Inc.?
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Ocumension Therapeutics, a China-based ophthalmic pharmaceutical platform company, today announced the expansion of their exclusive license agreements for the development and commercialization of YUTIQ® and DEXYCU® in certain Asian markets. Under the expanded agreements, Ocumension has made a one-time $9.5 million payment to EyePoint for rights to commercialize both products under their own brand names in South Korea and other jurisdictions across Southeast Asia and as the full and final prepayment of all remaining development, regulatory, and commercial sale milestone payments under the original license agreements.
“Ocumension is an important partner that shares our beliefs in the therapeutic potential of YUTIQ and DEXYCU for ocular diseases that represent growing and significant areas of unmet medical need,” said George Elston, Chief Financial Officer and Head of Corporate Development of EyePoint Pharmaceuticals. “We are delighted to expand our partnership with Ocumension to include the broader Asian marketplace. The payment from the expanded license agreements will support our operations and the ongoing clinical development of our pipeline, including our lead candidate, EYP-1901, a potential six-month sustained delivery therapy for wet age-related macular degeneration.”
“EyePoint’s YUTIQ and DEXYCU are important programs in our portfolio of ocular disease treatments that have the potential to replace current standards of care that lack long-term activity, especially given the impact of COVID-19 on patient desire to visit the doctor,” said Ye Liu, Chief Executive Officer of Ocumension. “We look forward to continuing our development efforts for both products in order to bring these innovative treatment options to patients in need across Asia.”
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc. (www.eyepointpharma.com) is a pharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company currently has two commercial products: DEXYCU®, the first approved intraocular product for the treatment of postoperative inflammation, and YUTIQ®, a three-year treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The Company's pipeline leverages its proprietary bioerodible Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential six-month anti-VEGF therapy initially targeting wet age-related macular degeneration. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts with offices in Basking Ridge, New Jersey. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.
About Ocumension Therapeutics
Ocumension Therapeutics is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing and commercializing first- or best-in-class ophthalmic therapies. The company’s vision is to provide a world-class pharmaceutical total solution to address significant unmet ophthalmic medical needs in China. Since the inception, Ocumension Therapeutics has focused on building a platform integrating specialized capabilities in each major functionality involved in an ophthalmic drug's development cycle, from research and development, manufacturing to commercialization. Ocumension Therapeutics believes its platform positions it well to achieve leadership in China ophthalmology, with a first-mover advantage over future competitors.
Nice play
Check NMTR
Question?? Chapter 11 plays,. If a stock is already down and out because the company hasn't officially announced it yet but are in process.
Avoid or Buy on the bottom?
LONE is EXPLODING, Low float Oil
LONE @ .44 20 mil float. OIL ??
FAMI 1.17m Float, Read>>>
This is the week it breaks $1.00 easily
The Farmmi Inc. (FAMI) shares are trading at higher $0.74.
To add more color to this target, the company’s high over the last year is $1.97 and the low is $0.31. Over the last 52 weeks, FAMI is down -62.45% while the S&P 500 is down -0.33%. The catalyst for this interesting swing was the company’s recent earnings report.
A Notable Earnings Report
FAMI booked profit margins of -1.00%, its Return on Equity (ROE) is -1.50%, and its Return on Assets is -1.20%. All told, it is clear that, FAMI needs to be on your watchlist.
Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. FAMI has a short ratio of 0.03 and outstanding shares of 11.93M.
Company Outlook
FAMI has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 0.5 million and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at -0.03. Farmmi Inc. FAMI also noted assets of $30.7 million at the end of the last quarter. Investors should also keep an eye on sector updates as FAMI has historically followed its peers on positive news.
All told, Farmmi Inc. FAMI has strung together solid data and demonstrated underlying fundamentals. At its current valuation, FAMI represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.
Farmmi Inc. FAMI is now commanding a market cap of 9.35M and a float of 1.17M. FAMI is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of FAMI stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in FAMI, either long or short, and we have not been compensated for this article.
https://oracledispatch.com/2020/07/17/farmmi-inc-nasdaqfami-is-gaining-momentum-on-earnings-catalyst/
FAMI .74 News today supplying U.S grocery. 3.2mil float, heavy short interest.
Bound to pop
ANCN, .80 this morning, hit 1.18 after hours.
ANCN on the bounce, 3.8 mil float
http://schrts.co/EReAIbjm
ANCN 3mil float, Bounce play, Chart
http://schrts.co/yBVGsQsj
Looking into this, what's your speculation?
Unbelievable drop
CTRM, Chart- oversold, Short Squeeze on yesterday's news
http://schrts.co/xKtawqWU
Have a great day weekend
CTRM, Chart- Low Float, oversold, Short Squeeze on yesterday's news
http://schrts.co/xKtawqWU
CTRM,look at L2, low float, Short squeeze
CTRM, .35 Here we go, easy double from here
CTRM, News, Short Squeeze coming
20m traded, 8mil float.
Gross revenue to increase by 900k
Castor Maritime Inc. Announces New Charter Agreement
Source: GlobeNewswire Inc.?
Castor Maritime Inc. (NASDAQ: CTRM), (“Castor” or the “Company”), a global shipping company specializing in the ownership of dry bulk vessels, announced that it entered today into a new time charter agreement with Oldendorff Carriers GMBH & Co KG in connection with its previously announced acquisition of a Panamax dry bulk carrier at a daily gross hire rate of $10,300. The charter agreement has an expected term of a minimum of three (3) months and up to a maximum of five (5) months and is expected to commence after the vessel’s delivery to the Company, sometime between the 5th and the 25th of August 2020. As a result of this charter agreement, the Company’s gross revenue is expected to increase by $0.9 million based on the minimum scheduled period of the time charter and could reach approximately $1.6 million should employment be extended to its maximum period.
Petros Panagiotidis, Chairman, Chief Executive Officer and Chief Financial Officer of Castor, commented:
“We are pleased to have been able to take advantage of the recent dry bulk market charter rate improvement by securing an attractive time charter contract for our recent acquisition. We believe that the recent vessel acquisition and the prompt securing of the time charter has further demonstrated our ability to act quickly and decisively in taking advantage of market opportunities presented to us. We are determined to continue taking advantage of such opportunities in the near future for the further growth of our fleet and our profitabilit
CTRM, News, Short Squeeze coming
20m traded, 8mil float.
Gross revenue to increase by 900k
Castor Maritime Inc. Announces New Charter Agreement
Source: GlobeNewswire Inc.?
Castor Maritime Inc. (NASDAQ: CTRM), (“Castor” or the “Company”), a global shipping company specializing in the ownership of dry bulk vessels, announced that it entered today into a new time charter agreement with Oldendorff Carriers GMBH & Co KG in connection with its previously announced acquisition of a Panamax dry bulk carrier at a daily gross hire rate of $10,300. The charter agreement has an expected term of a minimum of three (3) months and up to a maximum of five (5) months and is expected to commence after the vessel’s delivery to the Company, sometime between the 5th and the 25th of August 2020. As a result of this charter agreement, the Company’s gross revenue is expected to increase by $0.9 million based on the minimum scheduled period of the time charter and could reach approximately $1.6 million should employment be extended to its maximum period.
Petros Panagiotidis, Chairman, Chief Executive Officer and Chief Financial Officer of Castor, commented:
“We are pleased to have been able to take advantage of the recent dry bulk market charter rate improvement by securing an attractive time charter contract for our recent acquisition. We believe that the recent vessel acquisition and the prompt securing of the time charter has further demonstrated our ability to act quickly and decisively in taking advantage of market opportunities presented to us. We are determined to continue taking advantage of such opportunities in the near future for the further growth of our fleet and our profitabilit
Offtopic,
CTRM, check news , Low float. Churning at .34
FAMI about to bust loose. 4 Million float